KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Receivables (2016 - 2025)

Exact Sciences (EXAS) has disclosed Receivables for 12 consecutive years, with $298.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables rose 8.65% to $298.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $298.7 million, a 8.65% increase, with the full-year FY2025 number at $298.7 million, up 8.65% from a year prior.
  • Receivables was $298.7 million for Q4 2025 at Exact Sciences, down from $337.9 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $386.0 million in Q2 2025 to a low of $158.0 million in Q4 2022.
  • A 5-year average of $252.6 million and a median of $252.9 million in 2021 define the central range for Receivables.
  • Peak YoY movement for Receivables: skyrocketed 82.89% in 2021, then decreased 27.05% in 2022.
  • Exact Sciences' Receivables stood at $216.6 million in 2021, then decreased by 27.05% to $158.0 million in 2022, then surged by 55.23% to $245.3 million in 2023, then increased by 12.04% to $274.9 million in 2024, then increased by 8.65% to $298.7 million in 2025.
  • Per Business Quant, the three most recent readings for EXAS's Receivables are $298.7 million (Q4 2025), $337.9 million (Q3 2025), and $386.0 million (Q2 2025).